세계의 자가면역질환 진단 시장 보고서 : 제품 유형, 질환 유형, 검사 유형, 최종사용자, 지역별(2024-2032년)

The global autoimmune disease diagnosis market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.4% during 2024-2032. The increasing incidences of autoimmune diseases, rising sales of insurance policies, and the growing use of EMRs represent some of the key factors driving the market.

An autoimmune disease is a group of disorders wherein the immune system attacks the cells, tissues, and organs of the body. It can be caused by different medical conditions, such as systemic lupus erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes. It is associated with fatigue, joint pain and stiffness, skin rashes, fever, and digestive problems. It can also cause damage to organs and tissues, which leads to more severe symptoms like difficulty breathing, organ failure, or even death. It can be diagnosed via a combination of various approaches, such as taking a detailed medical history, performing a physical examination, blood tests to detect specific antibodies, imaging tests to look for damage or inflammation, and a biopsy to examine the affected tissue under a microscope.

Autoimmune Disease Diagnosis Market Trends:

The surging incidences of autoimmune diseases among individuals and the increasing aging population that are susceptible to develop such medical conditions represent one of the major factors driving the demand for autoimmune disease diagnosis around the world. Moreover, the rising awareness about autoimmune disease, its symptoms, diagnosis, and the easy availability of the treatment options is favoring the growth of the market. In addition, the growing implementation of health insurance policies that offer financial assistance for autoimmune disease diagnosis or treatment and reduce overall medical expenses is influencing the market positively. Apart from this, governing authorities of several countries are financing research and development (R&D) projects to study autoimmune diseases and develop new treatments. They are also investing in programs that aim to develop improved diagnostic methods for these medical disorders. Besides this, they are undertaking initiatives to offer quality healthcare facilities that are accessible to all. This, coupled with significant improvements in the diagnostic technologies, is strengthening the growth of the market. Furthermore, there is an increase in the use of electronic medical records (EMRs) to improve the accuracy and speed of autoimmune disease diagnosis as healthcare professionals have access to more comprehensive patient information. This, along with the rising adoption of telemedicine is catalyzing the demand for remote autoimmune disease diagnosis and monitoring technologies. Besides this, the growing demand for non invasive diagnosis, which is less painful as compared to traditional diagnostic procedures, is creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global autoimmune disease diagnosis market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product type, disease type, test type, and end-user.

Product Type Insights:

Consumables and Assay Kits

Instruments

The report has provided a detailed breakup and analysis of the autoimmune disease diagnosis market based on the product type. This includes consumables and assay kits, and instruments. According to the report, consumables and assay kits represented the largest segment.

Disease Type Insights:

Systemic Autoimmune Disease

Rheumatoid Arthritis

Psoriasis

Systemic Lupus Erythematosus (SLE)

Multiple Sclerosis

Others

Localized Autoimmune Disease

Inflammatory Bowel Disease

Type 1 Diabetes

Thyroid

Others

A detailed breakup and analysis of the autoimmune disease diagnosis market based on the disease type has also been provided in the report. This includes systemic autoimmune disease (rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis, and others) and localized autoimmune disease (inflammatory bowel disease, type 1 diabetes, thyroid, and others). According to the report, localized autoimmune disease (inflammatory bowel disease, type 1 diabetes, thyroid, and others) accounted for the largest market share.

Test Type Insights:

Routine Laboratory Tests

Inflammatory Markers

Autoantibodies and Immunologic Tests

Others

The report has provided a detailed breakup and analysis of the autoimmune disease diagnosis market based on the test type. This includes routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and others. According to the report, routine laboratory tests represented the largest segment.

End-User Insights:

Clinical Laboratories

Hospitals

Others

A detailed breakup and analysis of the autoimmune disease diagnosis market based on the end-user has also been provided in the report. This includes clinical laboratories, hospitals, and others. According to the report, clinical laboratories accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for autoimmune disease diagnosis. Some of the factors driving the North America autoimmune disease diagnosis market included the easy availability of treatments, technological advancements, extensive research and development (R&D) projects, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global autoimmune disease diagnosis market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, AESKU.GROUP, Danaher Corp., bioMerieux SA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hemagen Diagnostics, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech plc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

• 1. What is the size of the global autoimmune disease diagnosis market?
• 2. What has been the impact of COVID-19 on the global autoimmune disease diagnosis market?
• 3. What is the expected growth rate of the global autoimmune disease diagnosis market?
• 4. What are the key factors driving the global autoimmune disease diagnosis market?
• 5. What is the breakup of the global autoimmune disease diagnosis market based on the product type?
• 6. What is the breakup of the global autoimmune disease diagnosis market based on the disease type?
• 7. What is the breakup of the global autoimmune disease diagnosis market based on the test type?
• 8. What are the key regions in the global autoimmune disease diagnosis market?
• 9. Who are the key players/companies in the global autoimmune disease diagnosis market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Autoimmune Disease Diagnosis Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Consumables and Assay Kits
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Disease Type

• 7.1 Systemic Autoimmune Disease
  • 7.1.1 Market Trends
  • 7.1.2 Market Breakup by Type
    • 7.1.2.1 Rheumatoid Arthritis
    • 7.1.2.2 Psoriasis
    • 7.1.2.3 Systemic Lupus Erythematosus (SLE)
    • 7.1.2.4 Multiple Sclerosis
    • 7.1.2.5 Others
  • 7.1.3 Market Forecast
• 7.2 Localized Autoimmune Disease
  • 7.2.1 Market Trends
  • 7.2.2 Market Breakup by Type
    • 7.2.2.1 Inflammatory Bowel Disease
    • 7.2.2.2 Type 1 Diabetes
    • 7.2.2.3 Thyroid
    • 7.2.2.4 Others
  • 7.2.3 Market Forecast

8 Market Breakup by Test Type

• 8.1 Routine Laboratory Tests
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Inflammatory Markers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Autoantibodies and Immunologic Tests
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by End-User

• 9.1 Clinical Laboratories
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Hospitals
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 AESKU.GROUP
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Danaher Corp.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 SWOT Analysis
  • 14.3.4 bioMerieux SA
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Bio-Rad Laboratories Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 PerkinElmer Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Hemagen Diagnostics, Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Inova Diagnostics, Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Myriad Genetics, Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Quest Diagnostics Incorporated
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Siemens Healthineers AG
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
  • 14.3.12 SQI Diagnostics
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
  • 14.3.13 Thermo Fisher Scientific Inc.
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis
  • 14.3.14 Trinity Biotech plc
    • 14.3.14.1 Company Overview
    • 14.3.14.2 Product Portfolio
    • 14.3.14.3 Financials
    • 14.3.14.4 SWOT Analysis